Analytical Data
-
Gene name
BCL6
-
简介
BCL6 is a key transcriptional repressor of germinal centers and regulates multiple biological functions and lineages. It forms a complex with corepressors and histone deacetylase, directly binds to 5'-TTCCTAGAA-3', and inhibits genes involved in differentiation, inflammation, apoptosis and cell cycle control in GC B cells. BCL6 Protein, Human is the recombinant human-derived BCL6 protein, expressed by E. coli , with tag free.
- Application
-
Species
Human
-
Source
E. coli
-
Tag
Tag Free
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P41182
-
Expression Region
M1-C706
-
Protein Length
Full Length
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The BCL6 protein, a transcriptional repressor, plays a critical role in regulating immune responses and maintaining the balance between cell proliferation and apoptosis. It is predominantly expressed in germinal center B cells and has been implicated in various forms of lymphoma, particularly diffuse large B-cell lymphoma (DLBCL). The dysregulation of BCL6 due to chromosomal translocations and mutations underlines its significance as an oncogenic driver. Research into BCL6 and its functions has highlighted its multifaceted roles in gene expression, cell signaling, and the immune system, making it a promising target for therapeutic interventions. Recent studies have focused on understanding the molecular mechanisms by which BCL6 influences tumorigenesis, including its interactions with other transcription factors, co-repressors, and the epigenetic landscape of target genes. By elucidating these pathways, researchers aim to develop innovative approaches for treating BCL6-driven malignancies, which may include the design of small-molecule inhibitors or monoclonal antibodies that disrupt BCL6 function. Furthermore, BCL6’s involvement in other non-hematological tumors has expanded the scope of its research, suggesting it could also serve as a biomarker for cancer prognosis and therapeutic responses. Thus, the study of BCL6 not only provides insights into lymphoid malignancies but also offers potential avenues for broader cancer therapies.
